不同剂量干扰素α-2b雾化吸入治疗儿童病毒性肺炎的临床疗效

Clinical efficacy and immune function of different doses of interferon α-2b aerosol inhalation in the treat-ment of viral pneumonia in children

目的 探讨采用不同剂量干扰素α-2b雾化吸入治疗儿童病毒性肺炎的临床疗效及对免疫功能的影响。方法 选取2022年1月至2023年12月于河南省社旗县人民医院治疗的90例病毒性肺炎患儿,按治疗方法分为低剂量组(30例)、高剂量组(30例)与对照组(30例)。对照组采用常规治疗,低剂量组于对照组基础上采用低剂量干扰素α-2b治疗,高剂量组于对照组基础上采用高剂量干扰素α-2b治疗。比较3组临床疗效、免疫功能、炎性因子、临床症状消失时间及不良反应。结果 高剂量组与低剂量组治疗总有效率高于对照组,高剂量组与低剂量组治疗后CD4+及CD4+/CD8+高于对照组,CD8+低于对照组;高剂量组治疗后CD4+及CD4+/CD8+高于低剂量组,CD8+低于低剂量组,高剂量组与低剂量组治疗后C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)水平低于对照组;高剂量组治疗后CRP、TNF-α及IL-6水平低于低剂量组,高剂量组与低剂量组治疗后肺部音、喘憋、咳嗽、退热时间短于对照组;高剂量组肺部音、喘憋、咳嗽、退热时间短于低剂量组,差异有统计学意义(P<0.05);高剂量组与低剂量组治疗总有效率及3组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 儿童病毒性肺炎采用干扰素α-2b雾化吸入治疗能够改善患儿免疫功能,降低炎性因子水平,不良反应并未增加,且高剂量干扰素α-2b雾化吸入治疗效果更佳。

Objective To investigate the clinical efficacy and impact on immune function of different doses of interferonα-2b nebulized inhalation therapy for children with viral pneumonia.Methods A total of 90 children with viral pneumonia treated in People′s Hospital of Sheqi County from January 2022 to December 2023 were selected and divided into a low dose group,a high dose group and a control group according to different treatment,30 cases per group.The control group received conventional treatment,the low-dose group received low-dose interferonα-2b treatment on the basis of the same treatment as the control group,and the high-dose group received high-dose interferonα-2b treatment on the basis of the same treatment as the control group.The clinical efficacy,immune function,inflammatory factors,disappearance time of clinical symptoms,and adverse re-actions of the three groups were compared.Results The total effective rate of the high-dose and low-dose groups was higher than that of the control group.After treatment with interferonα-2b,the CD4+and CD4+/CD8+levels in the high-dose and low-dose groups were higher than those in the control group,while CD8+levels were lower than those in the control group;the CD4+and CD4+/CD8+levels in the high-dose group were higher than those in the low-dose group,while CD8+levels were lower than those in the low-dose group;the levels of C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6)in the high-dose and low-dose groups were lower than those in the control group;the levels of CRP,TNF-α,and IL-6 in the high-dose group were lower than those in the low-dose group;the disappearance time of lung rales,wheezing,coughing,and fever in the high-dose and low-dose groups was shorter than that in the control group;the disappearance time of lung rales,wheezing,coughing,and fever in the high-dose group was shorter than that in the low-dose group,with statistical differences(P<0.05).There was no statistically significant difference in the total effective rate between the high-dose group and the low-dose group(P>0.05);there was no statistically significant difference in the total incidence of adverse reactions among the three groups(P>0.05).Conclusion The treatment of interferonα-2b can improve the immune func-tion,reduce the level of inflammatory factors,without the adverse effects,and the effect ofα-2b is better.